Momelotinib information

Momelotinib
Clinical data
Other names	Momelotinib hydrochloride hydrate (JAN JP), Momelotinib dihydrochloride (USAN US)
License data	US DailyMed: Momelotinib;
Identifiers
PDB ligand	C87 (PDBe, RCSB PDB);

Momelotinib
Names
	Preferred IUPAC name N-(Cyanomethyl)-4-{2-[4-(morpholin-4-yl)anilino]pyrimidin-4-yl}benzamide
	Other names CYT-387; CYT-11387; GS-0387; Ojjaara;
Identifiers
CAS Number	1056634-68-4; as dihydrochloride: 1380317-28-1; 1841094-17-4;
3D model (JSmol)	Interactive image; as dihydrochloride: Interactive image;
ChEBI	CHEBI:91407;
ChEMBL	ChEMBL1078178;
ChemSpider	24676202;
DrugBank	DB11763; as dihydrochloride: DBSALT003445;
IUPHAR/BPS	7791;
KEGG	D10315; as dihydrochloride: D10358; D10889;
PubChem CID	25062766;
UNII	6O01GMS00P; as dihydrochloride: RBH995N496; LDX8893L5D;
	InChI InChI=1S/C23H22N6O2/c24-10-12-25-22(30)18-3-1-17(2-4-18)21-9-11-26-23(28-21)27-19-5-7-20(8-6-19)29-13-15-31-16-14-29/h1-9,11H,12-16H2,(H,25,30)(H,26,27,28) Key: ZVHNDZWQTBEVRY-UHFFFAOYSA-N;
	SMILES c1cc(ccc1c2ccnc(n2)Nc3ccc(cc3)N4CCOCC4)C(=O)NCC#N; as dihydrochloride: Cl.Cl.O=C(NCC#N)C1=CC=C(C=C1)C1=NC(NC2=CC=C(C=C2)N2CCOCC2)=NC=C1;
Properties
Chemical formula	C23H22N6O2
Molar mass	414.469 g·mol−1
Pharmacology
ATC code	L01EJ04 (WHO)
Routes of; administration	By mouth
Legal status	US: ℞-only; EU: Rx-only;
	Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). Infobox references

Momelotinib, sold under the brand name Ojjaara, is an anticancer medication used for the treatment of myelofibrosis.^[1] It is a Janus kinase inhibitor and it is taken by mouth.^[1]

The most common adverse reactions include dizziness, fatigue, bacterial infection, hemorrhage, thrombocytopenia, diarrhea, and nausea.^[4]

Momelotinib was approved for medical use in the United States in September 2023.^[1]^[4]^[5] It was approved in the EU in January 2024.^[6]

^ ^a ^b ^c ^d "Ojjaara- momelotinib tablet". DailyMed. U.S. National Library of Medicne. 15 September 2023. Archived from the original on 30 November 2023. Retrieved 20 September 2023.
^ "Omjjara EPAR". European Medicines Agency. 5 August 2011. Retrieved 18 March 2024.
^ "Omjjara Product information". Union Register of medicinal products. 26 January 2024. Retrieved 18 March 2024.
^ ^a ^b "FDA Roundup: September 19, 2023". U.S. Food and Drug Administration (FDA) (Press release). 19 September 2023. Archived from the original on 21 September 2023. Retrieved 20 September 2023. This article incorporates text from this source, which is in the public domain.
^ "Novel Drug Approvals for 2023". U.S. Food and Drug Administration (FDA). 15 September 2023. Archived from the original on 21 January 2023. Retrieved 20 September 2023. This article incorporates text from this source, which is in the public domain.
^ "GSK's Omjjara Authorized in EU for Treating Myelofibrosis With Anemia". MarketWatch. Retrieved 30 January 2024.

[Ojjaara_FDA_label-1] "Ojjaara- momelotinib tablet". DailyMed. U.S. National Library of Medicne. 15 September 2023. Archived from the original on 30 November 2023. Retrieved 20 September 2023.

[2] "Omjjara EPAR". European Medicines Agency. 5 August 2011. Retrieved 18 March 2024.

[3] "Omjjara Product information". Union Register of medicinal products. 26 January 2024. Retrieved 18 March 2024.

[FDA_PR_20230918-4] "FDA Roundup: September 19, 2023". U.S. Food and Drug Administration (FDA) (Press release). 19 September 2023. Archived from the original on 21 September 2023. Retrieved 20 September 2023. This article incorporates text from this source, which is in the public domain.

[Novel_Drug_Approvals_for_2023-5] "Novel Drug Approvals for 2023". U.S. Food and Drug Administration (FDA). 15 September 2023. Archived from the original on 21 January 2023. Retrieved 20 September 2023. This article incorporates text from this source, which is in the public domain.

[6] "GSK's Omjjara Authorized in EU for Treating Myelofibrosis With Anemia". MarketWatch. Retrieved 30 January 2024.

Momelotinib information

and 26 Related for: Momelotinib information

Momelotinib

Janus kinase inhibitor

Jaktinib

List of GSK plc products

Primary myelofibrosis

Erythropoietin

Interferon

Cytokine

Denosumab

Ritlecitinib

Ruxolitinib

Adipokine

Tofacitinib

TNF inhibitor

Elranatamab

Oclacitinib

Interferon alfa

Fas ligand

Deucravacitinib

Lymphokine

Interferon type I

Eltrombopag

Janus kinase

Upadacitinib

Belimumab

Etanercept

Names

Preferred IUPAC name N-(Cyanomethyl)-4-{2-[4-(morpholin-4-yl)anilino]pyrimidin-4-yl}benzamide
Other names CYT-387 CYT-11387 GS-0387 Ojjaara
Identifiers
CAS Number	1056634-68-4 as dihydrochloride: 1380317-28-1 1841094-17-4
3D model (JSmol)	Interactive image as dihydrochloride: Interactive image
ChEBI	CHEBI:91407
ChEMBL	ChEMBL1078178
ChemSpider	24676202
DrugBank	DB11763 as dihydrochloride: DBSALT003445
IUPHAR/BPS	7791
KEGG	D10315 as dihydrochloride: D10358 D10889
PubChem CID	25062766
UNII	6O01GMS00P as dihydrochloride: RBH995N496 LDX8893L5D
InChI InChI=1S/C23H22N6O2/c24-10-12-25-22(30)18-3-1-17(2-4-18)21-9-11-26-23(28-21)27-19-5-7-20(8-6-19)29-13-15-31-16-14-29/h1-9,11H,12-16H2,(H,25,30)(H,26,27,28) Key: ZVHNDZWQTBEVRY-UHFFFAOYSA-N
SMILES c1cc(ccc1c2ccnc(n2)Nc3ccc(cc3)N4CCOCC4)C(=O)NCC#N as dihydrochloride: Cl.Cl.O=C(NCC#N)C1=CC=C(C=C1)C1=NC(NC2=CC=C(C=C2)N2CCOCC2)=NC=C1
Properties
Chemical formula	C₂₃H₂₂N₆O₂
Molar mass	414.469 g·mol⁻¹
Pharmacology
ATC code	L01EJ04 (WHO)
Routes of administration	By mouth
Legal status	US: ℞-only^[1] EU: Rx-only^[2]^[3]
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). Infobox references